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Advanced  prostate  cancer  presented  with  hemolytic  uremic
syndrome
Síndrome  hemolítico  urémico  como  forma  de  presentación  de  cáncer
de  próstata  diseminado
Dear Director, and there was evidence of ARF (pCr: 7.5 mg/dl), accompanied
by anaemia (Hb: 12.6 g/dl), and thrombocytopenia (platelets:
9Ninety percent of the cases of haemolytic uraemic syndrome
(HUS) are caused by the ingestion of food contaminated with
61 × 10 /l), suggesting haemolysis (LDH 1600 U/l, with unde-
tectable haptoglobin and reticulocytosis). Urine speciﬁc grav-
ity was low, and there was microhaematuria, leukocyturia,
and proteinuria (<1 g/24 h) with no evidence of obstructive
uropathy in by ultrasound. Auto-immunity markers were nor-
mal, the patient showed increased schystocytes, negative
direct Coombs test, and preserved ADAMTS13 activity (25.4%).
Faeces were negative for STEC. After conﬁrming TMA/HUS,
the patient received HD and PP (Fig. 2B) and was diagnosed
with advanced prostate cancer (PSA: 760 ng/ml with bone
metastases, Fig. 1B), initiating treatment with bicalutamide. A
month later his renal function had normalised, with discrete
unexpectedly non-speciﬁc according to the consensus guide-Shiga toxin-producing Escherichia coli (STEC) (typical HUS),
that activates the classical complement pathway.1 There are
also thrombotic microangiopathies (TMA) secondary to drugs,
autoimmune diseases, and malignancies, these are related to
activation of the alternative complement pathway.2–5
We  present 3 patients from our hospital with advanced
prostate cancer who developed severe TMA/HUS and had a
good response to treatment (supportive, plasmapheresis, and
haemodialysis).
A 63-year old man, with no previous history of nephropa-
thy, who presented at the emergency room with malaise and
oliguria, no GI symptoms and without fever. Past medical
history and physical exam were unremarkable. The patient
had acute renal failure (pCr: 6.2 mg/dl), anaemia (Hb: 7.6 g/dl),
and thrombocytopenia (platelets: 49 × 109/l); elevated LDH
(1281 U/l), reticulocytosis, undetectable haptoglobin, and ele-
vated number of schystocytes. Urine showed dysmorphic red
blood cells, leukocyturia, and proteinuria (<1 g/24 h); obstruc-
tive uropathy was ruled out by ultrasound. Worsening renal
function occurred at 24 h, auto-immunity markers were nor-
mal, the direct Coombs test was negative, and the activity
of ADAMTS13 was normal (56.9%). Faeces were not tested
because of the absence of clinical signs and symptoms. The
patient was diagnosed with TMA/HUS and received daily
haemodialysis (HD) and plasmapheresis (PP).
Mean while, the patient was diagnosed of prostate ade-
nocarcinoma (PSA 195.6 ng/ml and a biopsy: Gleason 9) with
bone metastases (Fig. 1A). He completed 13 HD sessions, 18
PPs, and received bicalutamide, renal function and anaemia
recovered, with no evidence of haemolysis (Fig. 2A). The
patient was asymptomatic at the 8-month visit, and renal
function, Hb, and platelets count were normal.
An 82-year-old hypertensive COPD patient with a his-
tory of malaise, asthenia, micturition symptoms and oliguria.
The patient complained of cough with production of white
sputum, and a history of days of fever, with no GI symptoms
or evidence volume expansion. Severe infection was ruled out
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An 89-year old men  with diabetes and benign prostate
hyperplasia. He seek medical help because general dete-
rioration, abdominal pain, macroscopic haematuria, and
oliguria during the last a 6-days. No respiratory, cardiac,
or gastrointestinal symptoms a physical exam without
ﬁndings. The patient developed acute renal failure (pCr:
9.4 mg/dl), with haematuria and non-nephrotic protein-
uria; haemolytic anaemia (Hb: 10.1 g/dl, reticulocytosis, LDH:
4411 U/l, haptoglobin: 54 mg/dl, increased schystocytes) and
severe thrombocytopenia (platelets: 13 × 109/l). Obstructive
aetiology of acute renal failure was ruled out by ultrasound.
ADAMTS13 activity was preserved. The patient was diagnosed
of TMA/HUS, and was treated with HD and PP for 3 weeks,
with subsequent improvement of renal function, thrombo-
cytopenia, and anaemia (Fig. 2C). The patient was diagnosed
of prostate cancer and received speciﬁc treatment; the renal
function did not recover totally and remained with some resid-
ual renal failure.
In our three patients with TMA/HUS, disseminated
intravascular coagulation (DIC) was ruled out and the
diagnosis was made on the basis of the clinical history and
precipitating causes, since signs and symptoms of aHUS areo D, Slon F, Rullan AJ. Síndrome hemolítico urémico como forma
:194–196.
lines published in Nephrology (2013).6
Most cases of TMA/HUS are caused by STEC infections.
Yet, there have been reports of TMA/HUS secondary to drugs,
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cFig. 1 – (A) and (B) Bone scans showing 
utoimmune diseases, or malignancies.5,7,8 In patients from
ncologyin, the most common cause of TMA/HUS is in associ-
tion with chemotherapy drugs (mainly mitomycin), whereas
ases directly associated with malignancies are less common.
he largest series available consists of 168 patients; being GI
umours are the most common kind (26%), followed by breast
nd prostate cancer,9 thereby stressing the distinctiveness of
ur report.
Complete response to classical treatment for TMA/HUS
PP, HD, and supportive) was observed in the cases presented
ere. Based on good response to treatment with PP, the
eregulation of the alternative complement pathway, either
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ig. 2 – (A)–(C) Changes in haemoglobin, creatinine, and platelets
essions and plasmapheresis. The ﬁrst patient (1A) showed base
9 × 109/l. The patient underwent HD (magenta) and subsequent
reatment, diuresis and renal function were  gradually recovered 
ere similar for the second patient (1B), who also presented ana
P sessions, respectively, recovering one month later. The third p
essions, respectively, and showed recovery within one month. H
reatinine; PP: plasmapheresis.minated bone lesions in cases 1 and 2.
resulting from individual susceptibilities because of muta-
tions in regulatory proteins, or the presence of antibodies
against them, may lead to this condition.4 Resistance has also
been reported with a positive transient response to anti-C5a
(eculizumab).10
The association of TMA/HUS to malignancies compli-
cates the patient’s outcome; the therapy employed against
neoplasias are no always responsible for TMA/HUS. Early diag-
nosis and treatment of TMA/HUS may lead to resolution with
no sequelae. The thriving research concerning the comple-
ment will help identify the causes and the right treatment for
each patient.
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 over time in each case, concurrently with haemodialysis
line pCr of 6.29 mg/dl, Hb 7.6 g/dl, and platelet count
ly received PP (blue) every day. Two weeks after beginning
(13 HD sessions and 18 PP sessions). Baseline pCr ﬁgures
emia and thrombocytopenia. He received 10 and 17 HD and
atient (1C) had a similar behaviour, received 10 and 15
b: haemoglobin; HD: haemodialysis; pCr: plasma
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Utility  of  a predictive  model  fo
level 1  medical  care
Utilidad  de  un  modelo  de  predicció
crónica  en  una  unidad  de  primer  n
To the Editor,
The 2014 Spanish agreement Document for the Detection and
Management of Chronic Kidney Disease (CKD) recommended
that, in people with risk factors for development of and pro-
gression of CKD, the doctor should take certain preventive
measure.1
Despite these recommendations, the prevalence of CKD
continues to rise. In Mexico, one of the Latin American
countries with the highest prevalence of CKD,2,3 there was an
increase from 394 to 986 (patient per million) ppm from 2003
to 2007.To help primary care physicians to monitor groups at risk,
a model was constructed to predict probability of developing
CKD, depending on the different combinations of risk factors
that can be detected in a family medicine clinic.
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hronic  kidney  disease  in
para  la  enfermedad  renal
el  de  atención
This was a case–control study of patients treated in a
primary care unit of the Instituto Mexicano del Seguro Social (Mex-
ican Social Security Institute), Querétaro, Mexico, in 2013. The
sample size was calculated using the formula for two  propor-
tion, with a signiﬁcance level of 95%, test power 80%, OR 2.2,
considering a 1:1 ratio of patients with CKD for unpaired data
(n = 100 for each group).
Deﬁnition  of  groups
Cases: patients diagnosed with CKD by the renal depart-
ment, glomerular ﬁltration rate ≤60 mL/min, measured by 24 hurgos Ochoa M, Martínez Martínez ML, García Solís P, Villagrán
dad renal crónica en una unidad de primer nivel de atención.
urinary creatinine clearance, both sexes, and those older than
18 years.
Controls: patients without CKD, glomerular ﬁltration rate
≥61 mL/min measured by the Cockcroft–Gault formula on 2
